| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1815-12-10 |
| Identifiers | MRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729 |
| Document date | 1851-07-14 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: bleeding and pain after palliative pelvic radiation, two weeks after the first cycle of chemotherapy with pembrolizumab. [S]
Mrs. Lovelace returns four weeks after the consultation. The lung biopsy three weeks ago confirmed metastatic adenocarcinoma matching the cervical tumor. She completed five days of pelvic radiation, and the bleeding stopped within a week. She had the first cycle of carboplatin, paclitaxel and pembrolizumab two weeks ago, with nausea for two days. The constipation that brought her in a week ago settled within two days of the extra laxatives. Her average pelvic pain is 3 of 10 on long-acting morphine 15 mg twice a day, with a breakthrough dose on some days, and she is clear-headed in the mornings and working again. She feels low at times and finds it hard to sleep the night before treatment. She has no rash, diarrhea, or cough. [S]
| Element | Detail |
|---|---|
| Bleeding | Stopped a week after radiation |
| Pain | Average 3 of 10; breakthrough dose on some days; clear-headed |
| Chemotherapy | First cycle two weeks ago; nausea for two days |
| Bowels | Regular again since the sick visit |
| Mood | Low at times; PHQ-9 9 |
| System | Result | Finding |
|---|---|---|
| Genitourinary | Negative | No bleeding; light discharge; no urinary burning |
| Gastrointestinal | Negative | Bowels regular; no diarrhea |
| Integumentary | Negative | No rash |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Low at times; poor sleep before treatment; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 1849-06-03 to 1851-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 1851-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 1851-06-16 to 1851-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 1851-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 1851-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 1851-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 1851-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 1851-06-02 to 1851-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 1851-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 1851-06-30 to 1851-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 1851-06-30 to 1851-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 1851-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1851-07-14 | Body height | 165 | cm | S |
| 1851-07-14 | Body weight | 53.4 | kg | S |
| 1851-07-14 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 1851-07-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1851-07-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1851-07-14 | Heart rate | 84 | /min | S |
| 1851-07-14 | Respiratory rate | 16 | /min | S |
| 1851-07-14 | Body temperature | 36.6 | Cel | S |
| 1851-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1851-07-14 | Hemoglobin [Mass/volume] in Blood | 9.8 | g/dL | 12-15.5 g/dL | Low | S |
| 1851-07-14 | Leukocytes [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1851-07-14 | Neutrophils [#/volume] in Blood by Automated count | 2.2 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 1851-07-14 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1851-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1851-07-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1851-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M | 116 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 1851-07-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 1851-07-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S |
Vital signs recorded on 1851-07-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, not sedated; blood pressure 110/70, pulse 84, weight 53.4 kg |
| Mouth | No mucositis |
| Abdomen | Soft; mild suprapubic tenderness |
| Neurological | Sensation normal in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 9.8 g/dL, white cells 4.1, neutrophils 2.2, platelets 236 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.70 mg/dL, eGFR 116, ALT 22 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Due | Baseline four weeks ago; next due in two weeks, six weeks from baseline |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Due | Due in two to four weeks |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding since radiation |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | None |
| Examination | Peripheral neuropathy on paclitaxel | Before each paclitaxel cycle | Completed today | None |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Due | After four cycles |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 3 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation; nausea for two days after the cycle |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Constipation a week ago, resolved; daily laxatives |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change, and every 3 months | Up to date | Naloxone at home; locked storage |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | At diagnosis and periodically | Completed today | PHQ-9 9, mild; offered and accepted psycho-oncology counseling |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Completed today | Seen twice by the palliative care team |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)
Follow-up: Second cycle next week. Preventive visit in five weeks. Fourteen-week review after the restaging CT. Next scheduled visit 1851-08-18: periodic adult preventive visit. [S]